Displaying 631–640 of 658 for “retinal diseases”
Many different blindness-related awareness campaigns occur throughout the year. Not all of them are coordinated by the Foundation Fighting Blindness; however, we do support efforts to create a greater awareness of blindness.
Jul 11, 2019
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
Roster of the Foundation Fighting Blindness Scientific Advisory Board
Sep 18, 2018
Trial participants will receive intravitreal injections of APL-2, or a sham procedure (placebo), monthly or every other month. The injections are made into the vitreous, the soft gel in the middle of the eye.
Aug 7, 2017
Christian Guardino has been singing for as long as he can remember; it’s the seeing that is something new.
Jul 19, 2017
AGTC’s gene therapy uses a human-engineered virus — and adeno-associated virus or AAV — to deliver normal copies of retinoschisin to the patient’s retina.
Jan 29, 2014
Even in a well-designed clinical trial, the placebo effect can rear its head.
May 24, 2013
By Rich Shea
Jul 11, 2022
This year, the Foundation created a new fundraising initiative called Eye on the Prize, influenced by March Madness. The winner of the inaugural Eye on the Prize competition was Nicholls State University, raising $2,428. This winning team was led by Josh Cogswell, an assistant professor of management at Nicholls State University, who has his own personal connection to the Foundation’s mission.
Aug 23, 2021
Award-nominated recording artist Lachi has collaborated with some of the biggest names in the industry with millions of streams on her music. But with all her many amazing musical accomplishments, it wasn’t until a few years ago that she fully embraced herself as a legally blind artist who identifies with the disability community as closely as she does with music.